AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$OCUL

Kaiser Peter sold $33K of OCUL

Kaiser Peter (Chief Development Officer) sold 3,035 shares of OCULAR THERAPEUTIX, INC (OCUL) at $10.77 on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaiser Peter
Published Aug 26, 2026, 9:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OCUL
Neutral
high confidence
Mentioned
$OCUL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OCULNeutralLow
01

Why it matters

The disclosed sale is modest and does not provide a new trading catalyst.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming clinical data releases could affect future insider activity, but not reflected here.

Relevance 2/10Novelty 4/10Timing: 2026-08-24 filing (post‑market)

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$OCULNeutralHigh confidence
Context

Chief Development Officer sold 3,035 shares at $10.77 each ($32,687 total) via a 10b5‑1 plan on 2026‑08‑24.

Expected impact

No significant impact expected.

Evidence & confidence

The sale size is small relative to insider holdings and market cap; typical for routine 10b5‑1 plans.

Market effects

Sector

None; the transaction is company‑specific.

Regional

None; limited to OCUL shareholders.

Global

None

Counterpoint

What could challenge this read

If the insider had significant private information, the sell could signal downside, but the 10b5‑1 plan suggests routine execution.

Key entities

  • Officer
    Kaiser Peter

    Chief Development Officer of Ocular Therapeutix, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OCUL insider trading history →

Related articles

SEP 25
$OCULMedAI 8/10

Did Positive FDA Meeting Just Shift Ocular Therapeutix Stock Investment Narrative?

Ocular Therapeutix (OCUL) reported a positive Pre-NDA Meeting with the FDA for AXPAXLI, a treatment for wet AMD, and plans to file an NDA in Q4 2026. The company aims to use Phase 3 SOL-1 efficacy and interim SOL-R safety data. Analysts forecast revenue of $460.1M and earnings of $100.9M by 2029, with a 176% potential upside. The key risks include execution, long-term safety, and commercialization.

simplywall.st2 min
SEP 23
$OCULMedAI 8/10

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

Ocular Therapeutix (OCUL) announced a positive Pre-NDA meeting with the FDA for AXPAXLI, its treatment for wet age-related macular degeneration. The NDA is on track for submission in Q4 2026. AXPAXLI showed significant efficacy in clinical trials, with 74.1% of patients maintaining vision at Week 36, and up to 72% fewer injections compared to aflibercept. The company aims to leverage existing safety data to expedite the review process.

yahoo.com2 min
SEP 3
$OCULMedAI 8/10

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

Ocular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.

insidermonkey.com3 min